---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-122587"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T19:01:18.474654+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioXcel raises ~$6.2M in public offering of stock and warrants; cash runway into Q1 2025

## Summary
- Issued 5.6M shares and warrants, plus 9M pre-funded warrants, at $0.48 per share (or $0.479 for pre-funded).
- Net proceeds of ~$6.2M after underwriting discounts; use for SERENITY At-Home and TRANQUILITY In-Care trials.
- Cash runway expected into Q1 2025 when combined with existing cash; potential need for additional capital.
- Exercise price of 8.5M previously issued warrants reduced to $0.571 per share on Nov 21, 2024.

## SEC filing metadata
- accession: 0001104659-24-122587
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465924122587/0001104659-24-122587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465924122587/tm2428677d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-122587
- JSON: https://secwatch.observer/filing/0001104659-24-122587.json
- Plain text: https://secwatch.observer/filing/0001104659-24-122587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.